STAT January 23, 2024
Hello, everyone. Damian here with a look at some polarizing cancer data, a strange CEO transition, and the importance of New Year cheer.
The need-to-know this morning
- Sanofi is acquiring Inhibrx in a deal valued at up to $2.2 billion. The centerpiece of the transaction is an experimental drug, called INBRX-101, in mid-stage development for AATD, a disease that damages the liver and lungs. Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be spun out into a new company that will continue to be called Inhibrx.
- The FDA recommended the addition of new safety warnings to the prescribing labels of CAR-T cancer therapies, alerting physicians and patients to cases of secondary cancers that have occurred following...
Today's Sponsors
Today's Sponsor